Form 4 for PTCT PTC THERAPEUTICS, INC.
Accepted 2026-06-30 17:20:08 ET · period of report 2026-06-26 · accession 0001578850-26-000019 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-30 17:20 | 2026-06-26 | PTCT | Almstead Neil Gregory | CHIEF TECHNICAL OPS Off | M - OptEx | $38.10 | +8,130 | 67.9K | +14% | +$309.8K |
| DMT | 2026-06-30 17:20 | 2026-06-26 | PTCT | Almstead Neil Gregory | CHIEF TECHNICAL OPS Off | S - Sale+OE | $85.26 | -8,130 | 60.1K | -12% | -$693.2K |
| DMT | 2026-06-30 17:20 | 2026-06-26 | PTCT | Almstead Neil Gregory | CHIEF TECHNICAL OPS Off | M - OptEx | $0.00 | -8,130 | 19.7K | -29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-26 | M | A | 412 | $38.10 | 60,549 | D | — | — | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. |
| 2 | Common | Common Stock | 2026-06-26 | S | D | 412 | $85.23 | 60,137 | D | — | — | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. (F2) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.07 to $85.30 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2026-06-26 | M | A | 7,718 | $38.10 | 67,855 | D | — | — | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. |
| 4 | Common | Common Stock | 2026-06-26 | S | D | 7,718 | $85.26 | 60,137 | D | — | — | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. (F3) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.75 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-06-26 | M | D | 412 | $0.00 | 27,405 | D | $38.10 · — to 2032-01-06 | 412 Common Stock | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. (F4) Currently exercisable. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-06-26 | M | D | 7,718 | $0.00 | 19,687 | D | $38.10 · — to 2032-01-06 | 7,718 Common Stock | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. (F4) Currently exercisable. |